314 related articles for article (PubMed ID: 24639110)
1. Hypothesis: Tim-3/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages.
Gao L; Yu S; Zhang X
Cell Biochem Biophys; 2014 Sep; 70(1):273-7. PubMed ID: 24639110
[TBL] [Abstract][Full Text] [Related]
2. A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.
Kikushige Y; Miyamoto T; Yuda J; Jabbarzadeh-Tabrizi S; Shima T; Takayanagi S; Niiro H; Yurino A; Miyawaki K; Takenaka K; Iwasaki H; Akashi K
Cell Stem Cell; 2015 Sep; 17(3):341-52. PubMed ID: 26279267
[TBL] [Abstract][Full Text] [Related]
3. [A TIM-3/galectin-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemia progression].
Kikushige Y
Rinsho Ketsueki; 2016 Apr; 57(4):412-6. PubMed ID: 27169443
[TBL] [Abstract][Full Text] [Related]
4. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
Kikushige Y; Akashi K
Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
[TBL] [Abstract][Full Text] [Related]
6. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
[TBL] [Abstract][Full Text] [Related]
7. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
Kikushige Y; Miyamoto T
Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
[TBL] [Abstract][Full Text] [Related]
8. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells.
Lee WS; Ye Z; Cheung AMS; Goh YPS; Oh HLJ; Rajarethinam R; Yeo SP; Soh MK; Chan EHL; Tan LK; Tan SY; Chuah C; Chng WJ; Connolly JE; Wang CI
Mol Cancer Ther; 2021 Sep; 20(9):1702-1712. PubMed ID: 34158344
[TBL] [Abstract][Full Text] [Related]
9. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
[TBL] [Abstract][Full Text] [Related]
10. One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia.
Wang Z; Chen J; Wang M; Zhang L; Yu L
Front Immunol; 2021; 12():618710. PubMed ID: 33868234
[TBL] [Abstract][Full Text] [Related]
11. Galectins as regulators of cell survival in the leukemia niche.
Ruvolo PP
Adv Biol Regul; 2019 Jan; 71():41-54. PubMed ID: 30245264
[TBL] [Abstract][Full Text] [Related]
12. TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways.
Kikushige Y
Cancer Sci; 2021 Sep; 112(9):3419-3426. PubMed ID: 34159709
[TBL] [Abstract][Full Text] [Related]
13. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
Kikushige Y; Miyamoto T
Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
[TBL] [Abstract][Full Text] [Related]
14. Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells.
Gonçalves Silva I; Gibbs BF; Bardelli M; Varani L; Sumbayev VV
Oncotarget; 2015 Oct; 6(32):33823-33. PubMed ID: 26413815
[TBL] [Abstract][Full Text] [Related]
15. Oridonin Could Inhibit Inflammation and T-cell Immunoglobulin and Mucin-3/Galectin-9 (TIM-3/Gal-9) Autocrine Loop in the Acute Myeloid Leukemia Cell Line (U937) as Compared to Doxorubicin.
Nasri F; Sadeghi F; Behranvand N; Samei A; Bolouri MR; Azari T; Abdollahi E; Ghazizadeh F; Motevalian M; Hassan ZM; Falak R
Iran J Allergy Asthma Immunol; 2020 Dec; 19(6):602-611. PubMed ID: 33463129
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia.
Wu Z; Ou J; Liu N; Wang Z; Chen J; Cai Z; Liu X; Yu X; Dai M; Zhou H
Cancer Med; 2023 Apr; 12(7):8956-8969. PubMed ID: 36545697
[TBL] [Abstract][Full Text] [Related]
17. microRNA-1246-containing extracellular vesicles from acute myeloid leukemia cells promote the survival of leukemia stem cells via the LRIG1-meditated STAT3 pathway.
Chen L; Guo Z; Zhou Y; Ni J; Zhu J; Fan X; Chen X; Liu Y; Li Z; Zhou H
Aging (Albany NY); 2021 Apr; 13(10):13644-13662. PubMed ID: 33893245
[TBL] [Abstract][Full Text] [Related]
18. [TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in human acute myeloid leukemia].
Sakoda T; Kikushige Y
Rinsho Ketsueki; 2023; 64(6):547-552. PubMed ID: 37407480
[TBL] [Abstract][Full Text] [Related]
19. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li H; Wu K; Tao K; Chen L; Zheng Q; Lu X; Liu J; Shi L; Liu C; Wang G; Zou W
Hepatology; 2012 Oct; 56(4):1342-51. PubMed ID: 22505239
[TBL] [Abstract][Full Text] [Related]
20. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
